Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization
that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.We further our mission by:
MAPS is conducting a clinical trial of MDMA-assisted psychotherapy for PTSD in London, England, at King's College.
- Developing psychedelics and marijuana into prescription medicines
- Training therapists and working to establish a network of treatment centers
- Supporting scientific research into spirituality, creativity, and neuroscience
- Educating the public honestly about the risks and benefits of psychedelics and marijuanaWe envision a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.
MAPS is partnering on the local study with Supporting Wounded Veterans
(SWV), a group that focuses on five elements of rehabilitation, each critical in a Veteran's transition from military discharge to enduring meaningful civilian life. SWV is committed to aiding the mental and physical health journeys for our Veterans and those closest to them.As a non-profit organization focused on strengthening mental health services,
MAPS is committed to protecting the safety of our study staff and clinical trial participants. We are taking active measures to minimize the risk of exposure to the COVID-19 virus and adhere to physical distancing.
As a result of this initiative,
all of our clinical trials enrolling healthy volunteer participants are temporarily postponed. For our clinical trials treating participants with PTSD, the risks and benefits of ongoing participation for the current participants and study staff are constantly being weighed and determined on a case-by-case basis. All visits that can be conducted remotely are being done using teleconferencing. At this time, about half of our study sites are continuing with in-person day-long experimental sessions with MDMA or placebo, although this number is likely to decrease if the risk of exposure and public health interventions continues to increase. New enrollment of participants is temporarily on hold, and focus is being shifted to clinical trial protocols which can be done entirely by online visits. Our mission to maximize mental health and public benefit is more important than ever before.
Despite these trying times, we will continue to lead the way in offering high-quality psychedelic research and education.